Literature DB >> 18528940

Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

Kenneth-K Yan1, Marianne Guirgis, Thuy Dinh, Jacob George, Anouk Dev, Alice Lee, Amany Zekry.   

Abstract

AIM: To conduct a multicentre retrospective review of virological response rates in Asians infected with genotype 1 chronic hepatitis C (CHC) treated with combination interferon and ribavirin and then to compare their responses to that among Caucasians.
METHODS: Asian patients infected with genotype 1 CHC treated at 4 Australian centres between 2001 to 2005 were identified through hospital databases. Baseline demographic characteristics, biochemical, virological and histological data and details of treatment were collected. Sustained virological responses (SVR) in this cohort were then compared to that in Caucasian subjects, matched by genotype, age, gender and the stage of hepatic fibrosis.
RESULTS: A total of 108 Asians with genotype 1 CHC were identified. The end of treatment response (ETR) for the cohort was 79% while the SVR was 67%. Due to the relatively advanced age of the Asian cohort, only sixty-four subjects could be matched with Caucasians. The ETR among matched Asians and Caucasians was 81% and 56% respectively (P = 0.003), while the SVR rates were 73% and 36% (P < 0.001) respectively. This difference remained significant after adjusting for other predictive variables.
CONCLUSION: Genotype 1 CHC in Asian subjects is associated with higher rates of virological response compared to that in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528940      PMCID: PMC2716597          DOI: 10.3748/wjg.14.3416

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy.

Authors:  P Kimball; R K Elswick; M Shiffman
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

2.  Racial differences in HLA class II associations with hepatitis C virus outcomes.

Authors:  C L Thio; D L Thomas; J J Goedert; D Vlahov; K E Nelson; M W Hilgartner; S J O'Brien; P Karacki; D Marti; J Astemborski; M Carrington
Journal:  J Infect Dis       Date:  2001-05-30       Impact factor: 5.226

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response.

Authors:  Kazushi Sugimoto; Jason Stadanlick; Fusao Ikeda; Colleen Brensinger; Emma E Furth; Harvey J Alter; Kyong-Mi Chang
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

5.  Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Authors:  Matthew G Law; Gregory J Dore; Nicky Bath; Sandra Thompson; Nick Crofts; Kate Dolan; Wendy Giles; Paul Gow; John Kaldor; Stuart Loveday; Elizabeth Powell; Jenean Spencer; Alex Wodak
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

6.  High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

Authors:  Brian L Bressler; Maha Guindi; George Tomlinson; Jenny Heathcote
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

7.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

Authors:  Hossein Poustchi; Francesco Negro; Jason Hui; Ian Homer Y Cua; Laura Rubbia Brandt; James G Kench; Jacob George
Journal:  J Hepatol       Date:  2007-10-01       Impact factor: 25.083

10.  Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome.

Authors:  Anouk T Dev; Rhonda McCaw; Vijaya Sundararajan; Scott Bowden; William Sievert
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

View more
  21 in total

1.  Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital.

Authors:  Kenneth Kar-Lung Yan; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

Review 2.  Capillaria hepatica in China.

Authors:  Chao-Ding Li; Hui-Lin Yang; Ying Wang
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

3.  The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India.

Authors:  Siddapuram Sivaprasad; Padaki Nagaraja Rao; Rajesh Gupta; Kaitha Ashwini; Duvvuru Nageshwar Reddy
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

4.  Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.

Authors:  Ajit Sood; Vandana Midha; Omesh Goyal; Syed Hissar; Suresh Kumar Sharma; Pankaj Khanna
Journal:  Indian J Gastroenterol       Date:  2014-03-12

5.  Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations.

Authors:  Benjy Yi-Min Soh; Rajneesh Kumar; Victoria Sze-Min Ekstrom; Clement Yi-Hao Lin; Sobhana Thangaraju; Hwee Huang Tan; Kwai Peng Chan; Lina Hui Lin Choong; Diana Teo; Wan Cheng Chow
Journal:  Singapore Med J       Date:  2018-06-21       Impact factor: 1.858

Review 6.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

7.  Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.

Authors:  Li-Sheng Wu; Hong Wang; Xiao-Ping Geng
Journal:  Exp Ther Med       Date:  2011-11-21       Impact factor: 2.447

8.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

9.  Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.

Authors:  Arghavan Haj-Sheykholeslami; Maryam Keshvari; Heidar Sharafi; Ali Pouryasin; Khalil Hemmati; Fatemeh Mohammadzadehparjikolaei
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

10.  Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.

Authors:  Giuseppe Indolfi; Chiara Azzari; Massimo Resti
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.